NMN in the European Union
Legal or not? Status as of 2026

Nicotinamide mononucleotide, better known as NMN, is a precursor of NAD+ — a molecule involved in the energy metabolism of cells. This is the basis for the entire marketing narrative of "longevity" and "cellular rejuvenation" that drives demand. From a lawyer's perspective, however, what matters is different: market popularity and legal status are two entirely separate things, and in the case of NMN they diverge remarkably sharply.

A product that consumers seek and can easily find in foreign online stores still operates in a legal grey zone within the European Union.

Why NMN is classified as a "novel food"

The starting point is Regulation (EU) 2015/2283 on novel foods. Under its logic, any ingredient that was not consumed to a significant degree in the Union before 15 May 1997 requires prior authorisation before it may be legally placed on the market. NMN has no documented history of significant consumption in Europe before that date — and that is precisely why it qualifies as a novel food. The consequence is clear: until NMN completes the full authorisation procedure, it may not be legally placed on the EU market either as a food or as a food supplement ingredient.

Where we stand today: an EFSA opinion is not an authorisation

In May 2026, the European Food Safety Authority (EFSA) issued a positive safety opinion on synthetic β-NMN — based on an application submitted by EffePharm. The opinion concludes that intake of up to 300 mg per day is safe for adults, excluding pregnant and breastfeeding women, assessing NMN as a source of niacin (vitamin B3). The same opinion covers two threads jointly — the safety of NMN as a novel food and its bioavailability as a source of nicotinamide in the context of Directive 2002/46/EC. For the industry, this is undoubtedly good news and a genuine step forward.

Here, however, begins the most common misunderstanding. A positive EFSA opinion is not an authorisation to sell. It is a scientific opinion — one stage of the procedure. For NMN to be legally placed on the market, a Commission implementing act is required, adding it to the Union List of novel foods, issued following a procedure involving Member States. As of today, no such act has been issued. This means that despite the positive scientific assessment, NMN still formally cannot be legally placed on the EU market. "Almost authorised" in legal language still means "not authorised".

flowchart LR
    A[Applicant\nsubmission] --> B[EFSA\nassessment]
    B --> C[Positive safety\nopinion]
    C --> D[Procedure with\nMember States]
    D --> E[Commission\nimplementing act]
    E --> F[Entry on Union\nList of Novel Foods]
    F --> G[Legal sale\non EU market]
    style C fill:#0f766e,stroke:#14b8a6,color:#e2e8f0
    style D fill:#1e293b,stroke:#f59e0b,color:#fbbf24
    style E fill:#1e293b,stroke:#64748b,color:#94a3b8
    style F fill:#1e293b,stroke:#64748b,color:#94a3b8
    style G fill:#1e293b,stroke:#64748b,color:#94a3b8

The trap: applicant-specific authorisation

This is the most important point of the entire puzzle and simultaneously the one most often overlooked. Novel food authorisation typically does not concern an ingredient "in general" as an abstract substance. It relates to a specific product, with a defined specification, from a specific producer and manufactured in a defined way. Moreover, the applicant who bore the cost of studies and the dossier may obtain five-year data protection — effectively an exclusivity over the novel food as so defined.

The practical implication is very concrete. Even when NMN is formally authorised, the first — and for some time perhaps the only — beneficiary will be the applicant. An importer bringing NMN from another source, for example a popular Japanese product, may still have no legal basis for its sale, despite "NMN already being authorised in the EU". It is no coincidence that even today only the applicant may communicate the positive EFSA opinion, while other NMN producers remain subject to the restrictions of the novel food regime.

flowchart TD
    A[Is my NMN legal\nto sell in the EU?] --> B{Is NMN on the\nUnion List of\nNovel Foods?}
    B -->|No| C[STOP: sale\nis illegal]
    B -->|Yes| D{Does the authorisation\ncover my source\nand specification?}
    D -->|No| E{Has the data\nprotection period\n5 years expired?}
    D -->|Yes| F[You may sell\nunder authorisation\nconditions]
    E -->|No| G[STOP: applicant\nexclusivity\nblocks sale]
    E -->|Yes| H{Does your NMN\nmeet the specification\non the Union List?}
    H -->|Yes| I[You may sell\nafter compliance\nverification]
    H -->|No| J[STOP: requires\nown authorisation]
    style C fill:#7f1d1d,stroke:#f87171,color:#fecaca
    style G fill:#7f1d1d,stroke:#f87171,color:#fecaca
    style J fill:#7f1d1d,stroke:#f87171,color:#fecaca
    style F fill:#064e3b,stroke:#10b981,color:#d1fae5
    style I fill:#064e3b,stroke:#10b981,color:#d1fae5

The grey zone and enforcement realities

For years, NMN has been and continues to be sold within the Union through grey-zone channels — until national supervisory authorities began enforcing the novel food classification. It is worth recalling the principle from general food law: responsibility for product compliance lies with the operator acting within the EU, typically the importer or distributor. It is they who bear the risk of market withdrawal decisions, sales bans or administrative sanctions. The mere fact that a product can be physically purchased in an online store determines nothing about its legality — and constitutes no line of defence before an authority.

NMN in the USA and Asia — why products exist even though they are problematic in the EU

The divergence between markets can be a source of illusions. In the United States, the FDA in September 2025 reversed its earlier position and confirmed that NMN is not excluded from the definition of a dietary supplement. In Japan and parts of Asia, NMN has been freely available for years. This explains where the many Japanese and American NMN products on the market come from. It is essential, however, to understand that legal status in the country of origin does not transfer to the European Union — legality in Tokyo or the USA does not create a basis for sale in Warsaw or Berlin.

What this means in practice

For anyone considering placing an NMN product on the EU market, common sense dictates several things. First — do not treat the EFSA opinion as a green light; for that, a Commission implementing act and entry on the Union List are required. Second — when authorisation does appear, verify whether it covers specifically the source and specification of NMN you intend to import, and whether it is protected by applicant exclusivity. Third — monitor the procedure status on an ongoing basis, because in this area the situation changes quarter by quarter. And finally, the claims question: even after authorisation, the strict rules of Regulation (EC) No 1924/2006 will apply, absolutely prohibiting the attribution of disease-treatment or disease-prevention properties to food — the entire "anti-aging" narrative in a medical sense will remain impermissible, and if NMN is authorised as a source of niacin, only approved claims relating to niacin will come into play.

Conclusions

NMN is a textbook example of the gap between market demand and the state of the law. The direction is positive — the EFSA opinion genuinely brings authorisation closer — but between "safe according to EFSA" and "legal to sell in my product" there remains a considerable distance, where the most important role is played by the mechanism of applicant-specific authorisation. An operator who treats the positive opinion as a signal to start may be seriously disappointed. One who treats it as a preview of market opening and checks the status of their specific source early enough has a chance to enter the market knowingly and lawfully.

Disclaimer: Tomasz Krawczyk — legal counsel specialising in EU and Polish food law and dietary supplements. supplemental.pl · foodlaw.ai. This material is for general information only and reflects the status as of 2026; it does not constitute legal advice in any individual matter. The regulatory status of NMN is changing dynamically — verify the current state before making business decisions.